Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT01727336 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
160
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated by the sponsor following unblinding of the Progression Free Survival endpoint.

Conditions

Interventions

Sponsor

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA